Vol. 48 | 2026.06.15 — 06.21 | Market Mood: 70 / 100 — Optimistic
The Medical & Bio domain is rapidly transforming, driven by advanced therapies, AI-driven discovery, and pervasive biosensing.
- Pharma 4.0 achieves 75% efficiency in CGT production, expanding market to $66B+.
- CRISPR & base editing show 87% in vivo efficacy (HAE), with Phase 3 success and expanded reach via LNPs/BBB-penetrating biologics.
- AI platforms secure $2.1B, streamlining molecular design and bioprocess QC.
- First OTC CGM approval signals expanding biosensor clinical applications.
Western R&D directors and tech investors must prioritize strategic M&A, advanced manufacturing, and AI integration for competitive advantage and patient access. This week’s data is pivotal for strategic investments and R&D initiatives.
This infographic lets you judge at a glance whether the Full Intelligence Report is worth reading.
If the infographic makes you want to read the full report, please click the download button below.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments